These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26363997)

  • 1. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferonopathies in pediatric rheumatology.
    Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDA5-Associated Neuroinflammation and the Singleton-Merten Syndrome: Two Faces of the Same Type I Interferonopathy Spectrum.
    Buers I; Rice GI; Crow YJ; Rutsch F
    J Interferon Cytokine Res; 2017 May; 37(5):214-219. PubMed ID: 28475458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes.
    Bursztejn AC; Briggs TA; del Toro Duany Y; Anderson BH; O'Sullivan J; Williams SG; Bodemer C; Fraitag S; Gebhard F; Leheup B; Lemelle I; Oojageer A; Raffo E; Schmitt E; Rice GI; Hur S; Crow YJ
    Br J Dermatol; 2015 Dec; 173(6):1505-13. PubMed ID: 26284909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I interferonopathies: a novel set of inborn errors of immunity.
    Crow YJ
    Ann N Y Acad Sci; 2011 Nov; 1238():91-8. PubMed ID: 22129056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferonopathies: From concept to clinical practice.
    Mendonça LO; Frémond ML
    Best Pract Res Clin Rheumatol; 2024 Sep; 38(3):101975. PubMed ID: 39122631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Insights into the Structural Dynamics of MDA5 Variants Associated with Aicardi-Goutières Syndrome and Singleton-Merten Syndrome.
    Gosu V; Sasidharan S; Saudagar P; Lee HK; Shin D
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel pathogenic variant p.Asp797Val in IFIH1 in a Japanese boy with overlapping Singleton-Merten syndrome and Aicardi-Goutières syndrome.
    Hasegawa K; Tanaka H; Futagawa N; Miyahara H; Higuchi Y; Tsukahara H
    Am J Med Genet A; 2022 Jan; 188(1):249-252. PubMed ID: 34453469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic interferonopathies: An overview.
    Eleftheriou D; Brogan PA
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?
    Fiehn C
    Curr Rheumatol Rep; 2017 Aug; 19(10):61. PubMed ID: 28844088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aicardi-Goutières syndrome and the type I interferonopathies.
    Crow YJ; Manel N
    Nat Rev Immunol; 2015 Jul; 15(7):429-40. PubMed ID: 26052098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutières syndrome.
    Tüngler V; Silver RM; Walkenhorst H; Günther C; Lee-Kirsch MA
    Br J Dermatol; 2012 Jul; 167(1):212-4. PubMed ID: 22356656
    [No Abstract]   [Full Text] [Related]  

  • 14. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus.
    Abe J; Izawa K; Nishikomori R; Awaya T; Kawai T; Yasumi T; Hiragi N; Hiragi T; Ohshima Y; Heike T
    Rheumatology (Oxford); 2013 Feb; 52(2):406-8. PubMed ID: 22829693
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
    Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human disease phenotypes associated with mutations in TREX1.
    Rice GI; Rodero MP; Crow YJ
    J Clin Immunol; 2015 Apr; 35(3):235-43. PubMed ID: 25731743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.
    Meesilpavikkai K; Dik WA; Schrijver B; van Helden-Meeuwsen CG; Versnel MA; van Hagen PM; Bijlsma EK; Ruivenkamp CAL; Oele MJ; Dalm VASH
    Arthritis Rheumatol; 2019 May; 71(5):829-831. PubMed ID: 30666809
    [No Abstract]   [Full Text] [Related]  

  • 19. Type I interferonopathies: mendelian type I interferon up-regulation.
    Crow YJ
    Curr Opin Immunol; 2015 Feb; 32():7-12. PubMed ID: 25463593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Editing in Interferonopathies.
    Frassinelli L; Galardi S; Ciafrè SA; Michienzi A
    Methods Mol Biol; 2021; 2181():269-286. PubMed ID: 32729086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.